切换至 "中华医学电子期刊资源库"

第五届中国出版政府奖音像电子网络出版物奖提名奖

中国科技核心期刊

中国科学引文数据库(CSCD)来源期刊

中华重症医学电子杂志 ›› 2026, Vol. 12 ›› Issue (03) : 279 -289. doi: 10.3877/cma.j.issn.2096-1537.2026.03.008

临床研究

血红蛋白与红细胞分布宽度比值在危重ARDS患者肾脏替代治疗中的L形关联
黎佩雯1,2, 方年新1,3,†(), 游俊廷2, 赖辉燕4   
  1. 1 524001 广东湛江,广东医科大学第一临床医学院
    2 523200 广东东莞,南方医科大学第十附属医院 东莞市人民医院急诊科
    3 523200 广东东莞,南方医科大学第十附属医院 东莞市人民医院呼吸与危重症医学科
    4 510515 广州,南方医科大学深圳临床医学院
  • 收稿日期:2026-03-26 出版日期:2026-08-28
  • 通信作者: 方年新
  • 基金资助:
    广东省东莞市社会发展科技项目(20221800906372); 广东省医学科学技术研究基金项目(B2024562)

L-shaped association between hemoglobin-to-red blood cell distribution width ratio and renal replacement therapy in critically ill patients with ARDS

Peiwen Li1,2, Nianxin Fang1,3,†(), Junting You2, Huiyan Lai4   

  1. 1 The First School of Clinical Medicine of Guangdong Medical University, Zhanjiang 524001, China
    2 Department of Emergency, the Tenth Affiliated Hospital of Southern Medical University, Dongguan People's Hospital, Dongguan 523200, China
    3 Department of Respiratory and Critical Care Medicine, the Tenth Affiliated Hospital of Southern Medical University, Dongguan People's Hospital, Dongguan 523200, China
    4 Shenzhen School of Clinical Medicine (Shenzhen Hospital), Southern Medical University, Guangzhou 510515, China
  • Received:2026-03-26 Published:2026-08-28
  • Corresponding author: Nianxin Fang
引用本文:

黎佩雯, 方年新, 游俊廷, 赖辉燕. 血红蛋白与红细胞分布宽度比值在危重ARDS患者肾脏替代治疗中的L形关联[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 279-289.

Peiwen Li, Nianxin Fang, Junting You, Huiyan Lai. L-shaped association between hemoglobin-to-red blood cell distribution width ratio and renal replacement therapy in critically ill patients with ARDS[J/OL]. Chinese Journal of Critical Care & Intensive Care Medicine(Electronic Edition), 2026, 12(03): 279-289.

目的

探讨血红蛋白与红细胞分布宽度比值(HRR)与危重急性呼吸窘迫综合征(ARDS)患者启动肾脏替代治疗(RRT)风险的关联。

方法

本研究为回顾性队列研究。从MIMIC-Ⅳ数据库中纳入2031例ARDS患者,收集人口学、生命体征、实验室指标、合并症、ICU早期用药及疾病严重程度评分等变量。根据HRR的四分位数将患者分为Q1:≤0.57 g/(dl·%)、Q2:>0.57~0.74 g/(dl·%)、Q3:>0.74~0.90 g/(dl·%)、Q4:>0.90 g/(dl·%)4组,4组HRR中位数分别为0.47(0.40~0.53)、0.65(0.61~0.69)、0.81(0.77~0.86)、1.01(0.95~1.10)g/(dl·%),计算各组RRT启动率。采用Cox回归、以ICU死亡为竞争事件的竞争风险模型及限制性立方样条分析入住ICU后首日首次测量的HRR与RRT启动风险的关联,并采用C指数及亚组分析评估预测区分度与效应异质性。

结果

385例(18.96%)患者启动RRT。与Q1组相比,Q2、Q3、Q4组RRT启动风险显著降低。该趋势在以ICU死亡为竞争事件的竞争风险模型中同样成立。HRR与RRT风险呈L形非线性关联,切点为0.668 g/(dl·%)。

结论

危重ARDS患者中,HRR与RRT启动风险呈L形负相关,较低的基线HRR提示较高的RRT风险,可作为辅助性早期风险分层指标之一,需联合其他临床指标综合评估。

Objective

To investigate the association between hemoglobin-to-red blood cell distribution width ratio (HRR) and the risk of renal replacement therapy (RRT) initiation in critically ill patients with acute respiratory distress syndrome (ARDS).

Methods

This retrospective cohort study included 2031 patients with ARDS from the MIMIC-Ⅳ database. Demographic, vital sign, laboratory, comorbidity, early ICU medication, and disease severity variables were collected. Patients were divided into four groups according to HRR quartiles: Q1 [≤0.57 g/(dl·%)], Q2 [>0.57–0.74 g/(dl·%)], Q3 [>0.74–0.90 g/(dl·%)], and Q4 [>0.90 g/(dl·%)]. The median HRR levels were 0.47 (0.40–0.53), 0.65 (0.61–0.69), 0.81 (0.77–0.86), and 1.01 (0.95–1.10) g/(dl·%), respectively. RRT initiation rates were calculated for each group. Cox regression, a competing-risk model with ICU mortality as the competing event, and restricted cubic spline analysis were used to evaluate the association between the first HRR measured on the first day after ICU admission and the risk of RRT initiation. C-index and subgroup analyses were used to evaluate predictive discrimination and effect heterogeneity.

Results

RRT was initiated in 385 patients (18.96%). Compared with the Q1 group, the risk of RRT initiation was significantly lower in the Q2, Q3, and Q4 groups. This trend was also observed in a competing-risk model using ICU mortality as the competing event. HRR exhibited an L-shaped nonlinear association with the risk of RRT initiation, with a cutoff value of 0.668 g/(dl·%).

Conclusion

In critically ill patients with ARDS, HRR is negatively and nonlinearly associated with the risk of RRT initiation in an L-shaped pattern. A lower baseline HRR is associated with a higher risk of RRT initiation, suggesting that HRR may serve as one of the auxiliary early risk stratification tools and should be used in combination with other clinical indicators.

表1 不同HRR分组下ARDS患者基线资料比较(2031例)
基线资料 总体 Q1(509例) Q2(509例) Q3(507例) Q4(506例) 统计值 P值
年龄(岁,
±s)
61.6±16.2 61.6±15.2 63.6±15.8 62.4±16.2 58.8±17.1 F=7.994 <0.001
年龄≥65岁[例(%)] 928(45.7) 212(41.7) 267(52.5) 241(47.5) 208(41.1) χ2=17.716 0.001
男性[例(%)] 1153(56.8) 252(49.5) 248(48.7) 288(56.8) 365(72.1) χ2=73.037 <0.001
种族[例(%)] χ2=25.952 0.011
白种人 1187(58.4) 314(61.7) 318(62.5) 282(55.6) 273(54.0)
拉丁裔 96(4.7) 23(4.5) 19(3.7) 22(4.3) 32(6.3)
亚裔 72(3.5) 12(2.4) 20(3.9) 18(3.6) 22(4.3)
非洲裔 186(9.2) 52(10.2) 49(9.6) 50(9.9) 35(6.9)
其他/不明 490(24.1) 108(21.2) 103(20.2) 135(26.6) 144(28.5)
吸烟史[例(%)] 749(36.9) 192(37.7) 192(37.7) 183(36.1) 182(36.0) χ2=0.624 0.891
BMI[kg/m2,M(Q1,Q3)] 29.0(25.2,34.3) 28.2(24.2,33.7) 28.8(24.9,34.5) 29.6(25.6,35.0) 29.3(25.8,34.0) H=9.084 0.028
肥胖[例(%)] 913(45.0) 212(41.7) 227(44.6) 242(47.7) 232(45.9) χ2=4.016 0.260
入住外科ICU[例(%)] 367(18.1) 76(14.9) 110(21.6) 86(17.0) 95(18.8) χ2=8.288 0.040
GCS评分[分,M(Q1,Q3)] 15.0(14.0,15.0) 15.0(14.0,15.0) 15.0(14.0,15.0) 15.0(14.0,15.0) 15.0(14.0,15.0) H=0.615 0.893
APACHE Ⅱ评分[分,M(Q1,Q3)] 24.0(18.0,31.0) 27.0(21.0,33.0) 24.0(19.0,31.0) 23.0(17.0,30.0) 21.0(16.0,28.0) H=97.234 <0.001
高APACHE Ⅱ评分[例(%)] 957(47.1) 306(60.1) 245(48.1) 218(43.0) 188(37.2) χ2=58.348 <0.001
SIRS[例(%)] 1511(74.4) 379(74.5) 374(73.5) 387(76.3) 371(73.3) χ2=1.531 0.675
HRR[g/(dl·%),M(Q1,Q3)] 0.74(0.57,0.90) 0.47(0.40,0.53) 0.65(0.61,0.69) 0.81(0.77,0.86) 1.01(0.95,1.10) H=1903.124 <0.001
RDW[%,M(Q1,Q3)] 14.7(13.6,16.3) 17.7(16.0,19.6) 15.1(14.2,16.1) 14.2(13.4,15.1) 13.4(12.9,14.0) H=1079.414 <0.001
Hb[g/dl,M(Q1,Q3)] 10.8(9.1,12.6) 8.2(7.5,8.9) 9.9(9.2,10.6) 11.5(11.0,12.3) 13.8(12.9,14.8) H=1620.157 <0.001
eGFR[ml/(min·1.73m2),M(Q1,Q3)] 68.8(39.6,97.2) 56.9(31.1,94.2) 70.44(36.8,98.5) 67.50(40.2,99.0) 77.3(52.7,98.8) H=39.688 <0.001
UCR≥20[例(%)] 999(49.2) 286(56.2) 263(51.7) 245(48.3) 205(40.5) χ2=26.620 <0.001
WBC[×109/L,M(Q1,Q3)] 12.1(8.0,17.4) 12.0(7.3,18.5) 11.7(7.7,17.6) 12.1(8.1,17.0) 12.7(9.1,16.9) H=2.670 0.445
血Na+[mmol/L,M(Q1,Q3)] 138.0(135.0,142.0) 138.0(134.0,142.0) 138.0(135.0,142.0) 138.0(135.0,141.0) 139.0(136.0,141.0) H=3.561 0.313
血K+[mmol/L,M(Q1,Q3)] 4.2(3.7,4.7) 4.2(3.7,4.8) 4.2(3.7,4.6) 4.2(3.7,4.7) 4.2(3.8,4.7) H=2.567 0.463
血HCO3-[mmol/L,M(Q1,Q3)] 22.0(19.0,25.0) 21.0(18.0,25.0) 22.0(19.0,25.0) 22.0(19.0,26.0) 22.0(19.0,25.0) H=8.946 0.030
血糖过高[例(%)] 530(26.1) 96(18.9) 128(25.2) 135(26.6) 171(33.8) χ2=29.679 <0.001
高乳酸血症[例(%)] 895(44.1) 240(47.2) 198(38.9) 222(43.8) 235(46.4) χ2=8.653 0.034
脓毒症[例(%)] 1676(82.5) 417(81.9) 431(84.7) 407(80.3) 421(83.2) χ2=3.698 0.296
恶性肿瘤[例(%)] 316(15.6) 139(27.3) 83(16.3) 59(11.6) 35(6.9) χ2=88.400 <0.001
CKD[例(%)] 312(15.4) 91(17.9) 89(17.5) 86(17.0) 46(9.1) χ2=20.547 <0.001
COPD[例(%)] 315(15.5) 75(14.7) 98(19.3) 82(16.2) 60(11.9) χ2=10.998 0.012
用药[例(%)]
抗生素 1042(51.3) 275(54.0) 293(57.6) 257(50.7) 217(42.9) χ2=23.926 <0.001
糖皮质激素 156(7.7) 42(8.3) 39(7.7) 36(7.1) 39(7.7) χ2=0.475 0.924
肌肉松弛剂 404(19.9) 75(14.7) 109(21.4) 104(20.5) 116(22.9) χ2=12.280 0.006
利尿剂 229(11.3) 77(15.1) 55(10.8) 46(9.1) 51(10.1) χ2=10.845 0.013
表2 不同HRR分组下ARDS患者临床结局比较(2031例)
图1 ARDS患者RRT启动预测模型中各临床变量的相对重要性排名。红色文字为暴露因素;橘色文字为传统RRT预测标志物 注:ARDS为急性呼吸窘迫综合征;RRT为肾脏替代治疗;eGFR为估算肾小球滤过率;APACHEⅡ为急性生理学与慢性健康状况评估;HRR为血红蛋白与红细胞分布宽度比;CKD为慢性肾病;UCR为血尿素氮与肌酐比;WBC为白细胞计数;BMI为体质量指数;SIRS为系统性炎症反应综合征;COPD为慢性阻塞性肺疾病
图2 ARDS患者入住ICU后RRT启动风险的CIF曲线。图a为全部ARDS患者的RRT启动风险;图b为住ICU期间发生AKI的ARDS患者的RRT启动风险;图c为全部ARDS患者死亡风险 注:ARDS为急性呼吸窘迫综合征;RRT为肾脏替代治疗;CIF为累积发生率;AKI为急性肾损伤
表3 HRR四分位数的单因素、多因素Cox回归分析
图3 以ICU内死亡为RRT启动的竞争风险模型计算得到的RRT启动的校正风险比。竞争风险模型校正了年龄组、性别、种族、吸烟史、BMI、入住ICU类型、WBC、eGFR、UCR分组、血钠、血钾、血碳酸氢盐、血糖过高、高乳酸血症、GCS评分、高APACHEⅡ评分、SIRS、脓毒症、COPD、恶性肿瘤、CKD,以及抗生素、糖皮质激素、肌肉松弛剂、利尿剂等ICU后4 h内药物使用情况 注:RRT为肾脏替代治疗;aHRs为;BMI为体质量指数;WBC为白细胞计数;eGFR为估计肾小球滤过率;UCR为血尿素氮与肌酐比值;GCS为格拉斯哥昏迷指数;APACHE Ⅱ为急性生理学与慢性健康状况评估;SIRS为系统性炎症反应综合征;COPD为慢性阻塞性肺疾病;CKD为慢性肾病
图4 ICU内RRT启动概率与HRR的RCS分析。图a为全部ICU ARDS患者;图b为ICU住院期间发生AKI的ARDS患者。模型3校正了年龄组、性别、种族、吸烟史、BMI、入住ICU类型、WBC、eGFR、UCR分组、血钠、血钾、血碳酸氢盐、血糖过高、高乳酸血症、GCS评分、高APACHE II评分、SIRS、脓毒症、COPD、恶性肿瘤、CKD,以及抗生素、糖皮质激素、肌肉松弛剂、利尿剂等ICU后4 h内药物使用情况 注:RRT为肾脏替代治疗;HRR为血红蛋白与红细胞分布宽度比值;RCS为限制性立方样条;ARDS为急性呼吸窘迫综合征;AKI为急性肾损伤;BMI为体质量指数;WBC为白细胞计数;eGFR为估计肾小球滤过率;UCR为血尿素氮与肌酐比值;GCS为格拉斯哥昏迷指数;APACHE Ⅱ为急性生理学与慢性健康状况评估;SIRS为系统性炎症反应综合征;COPD为慢性阻塞性肺疾病;CKD为慢性肾病
图5 不同模型的C指数。图a为预测RRT启动;图b为预测ICU死亡;误差棒代表95%CI 注:RRT为肾脏替代治疗;UCR为血尿素氮与肌酐比值;SIRS为系统性炎症反应综合征;HRR为血红蛋白与红细胞分布宽度比值
图6 HRR的亚组分析森林图 注:HRR为血红蛋白与红细胞分布宽度比值;eGFR为估计肾小球滤过率;SIRS为系统性炎症反应综合征;COPD为慢性阻塞性肺疾病
1
Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome[J]. Nat Rev Dis Primers, 2019, 5(1): 18.
2
薛燕红, 杨秀芬. 脓毒症急性肺损伤的发病机制及治疗进展[J]. 河北医科大学学报, 2024, 45(4): 406-412.
3
Pickkers P, Darmon M, Hoste E, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management[J]. Intensive Care Med, 2021, 47(8): 835-850.
4
Mattedi FZ, Ribeiro HS, Busatto GF, et al. Acute respiratory distress syndrome and acute kidney injury in critically ill patients: a scoping review on this lung-kidney crosstalk[J]. J Crit Care, 2026, 93: 155445.
5
Gao Y, Qi ZD, Liu RJ, et al. A multi-center cross-sectional study on blood purification among adult patients in intensive care unit in China: a study protocol[J]. Chin Med J (Engl), 2019, 132(10): 1208-1211.
6
Ziaka M, Exadaktylos A. Fluid management strategies in critically ill patients with ARDS: a narrative review[J]. Eur J Med Res, 2025, 30(1): 401.
7
Chi G, Lee JJ, Montazerin SM, et al. Prognostic value of hemoglobin-to-red cell distribution width ratio in cancer: a systematic review and meta-analysis[J]. Biomark Med, 2022, 16(6): 473-482.
8
Eyiol A, Ertekin B. The relationship between hemoglobin-to-red cell distribution width (RDW) ratio (HRR) and mortality in stroke patients[J]. Eur Rev Med Pharmacol Sci, 2024, 28(4): 1504-1512.
9
Eyiol A, Eyiol H, Sahin AT. Evaluation of HRR (hemoglobin/red blood cell distribution width ratio) and RAR (red blood cell distribution width/albumin ratio) in myocarditis patients: associations with various clinical parameters[J]. Int J Gen Med, 2024, 17: 5085-5093.
10
Matthay MA, Arabi Y, Arroliga AC, et al. A new global definition of acute respiratory distress syndrome[J]. Am J Respir Crit Care Med, 2024, 209(1): 37-47.
11
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801–810.
12
Khwaja A. KDIGO clinical practice guidelines for acute kidney injury[J]. Nephron Clin Pract, 2012, 120(4): c179-184.
13
Efthimiou O, Seo M, Chalkou K, et al. Developing clinical prediction models: a step-by-step guide[J]. BMJ, 2024, 386: e078276.
14
Livingston EH, Lewis RJ. JAMA guide to statistics and methods[M]. New York: McGraw Hill Professional, 2019.
15
Inker LA, Eneanya ND, Coresh J, et al. New creatinine- and cystatin C-based equations to estimate GFR without race[J]. N Engl J Med, 2021, 385(19): 1737-1749.
16
Paulus MC, Melchers M, van Es A, et al. The urea-to-creatinine ratio as an emerging biomarker in critical care: a scoping review and meta-analysis[J]. Crit Care, 2025, 29(1):175.
17
Sun P, Zhang F, Chen C, et al. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China[J]. Oncotarget, 2016, 7(27): 42650-42660.
18
Zhou J, Du W, Huang H, et al. HRR as a predictor of lung health: insights from the NHANES database[J]. Front Med (Lausanne), 2025, 12: 1503142.
19
Xanthopoulos A, Giamouzis G, Dimos A, et al. Red blood cell distribution width in heart failure: pathophysiology, prognostic role, controversies and dilemmas[J]. J Clin Med, 2022, 11(7): 1951.
20
周科, 杜贤荣, 冯建宏. 脓毒症患者预后与红细胞体积分布宽度和中性粒细胞/淋巴细胞比值的关系[J]. 中国临床研究, 2023, 36(10): 1500-1503, 1508.
21
He R, Liao Y, Men L, et al. Longitudinal modeling of red blood cell distribution width dynamics and mortality risk in critically ill patients with sepsis-associated acute kidney injury[J]. PLoS One, 2025, 20(10): e0333605.
22
Ramires MLV, Leite MFB, Lo DZY, et al. Relation between red blood cell distribution width and acute kidney injury in patients with sepsis[J]. Einstein (Sao Paulo), 2022, 20: eAO6828.
23
Cai N, Jiang M, Wu C, et al. Red cell distribution width at admission predicts the frequency of acute kidney injury and 28-day mortality in patients with acute respiratory distress syndrome[J]. Shock, 2022, 57(3): 370-377.
24
Hayden SJ, Albert TJ, Watkins TR, et al. Anemia in critical illness: insights into etiology, consequences, and management[J]. Am J Respir Crit Care Med, 2012, 185(10): 1049-1057.
25
Li M, Li H, Zhong W, et al. Hemoglobin-to-red cell distribution width ratio was associated with cardiovascular diseases and death[J]. J Clin Med, 2025, 14(13): 4464.
26
Xiong J, Tan H, Mao S, et al. Association between hemoglobin-to-red blood cell distribution width ratio and 30-day mortality in patients with acute pancreatitis: data from MIMIC-Ⅲ and MIMIC-Ⅳ[J]. Turk J Gastroenterol, 2024, 35(8): 651-664.
27
Xu X, Yang R, Yin Y, et al. Association of hemoglobin-to-red blood cell distribution width ratio with mortality in critically ill patients with heart failure and acute kidney injury: insights from the MIMIC-Ⅳ database[J]. BMC Cardiovasc Disord, 2025, 25(1): 214.
28
Lai T, Liang Y, Guan F, et al. Trends in hemoglobin-to- red cell distribution width ratio and its prognostic value for all-cause, cancer, and cardiovascular mortality: a nationwide cohort study[J]. Sci Rep, 2025, 15(1): 7685.
[1] 陈静, 曲东, 刘霜. 急性呼吸窘迫综合征细胞治疗机制及临床应用研究进展[J/OL]. 中华实验和临床感染病杂志(电子版), 2025, 19(06): 327-334.
[2] 叶恭杰, 郑施, 翁一如, 董绉绉. NMF标准在肝移植术后急性肾损伤患者肾脏替代治疗时机选择中的应用价值[J/OL]. 中华移植杂志(电子版), 2026, 20(04): 260-267.
[3] 张阿妮, 王冠华, 袁亚迎, 任志超, 梁杰, 赵蕊新, 陈妍, 郭娟妮, 康瑞. 肺超声联合膈肌超声检测指标预测急性呼吸窘迫综合征患者拔管的临床研究—附126例分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(03): 392-398.
[4] 甘志新, 胡雍军, 杨倩, 胡明冬. 75例急性呼吸窘迫综合征的临床特征及预后分析[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(02): 221-226.
[5] 梅春霞, 冯霞, 邬海桥, 刘攀, 李昆霖, 徐智, 刘禹. 肺损伤预测评分联合血管生成素-2对肺部感染并发急性呼吸窘迫综合征的预测意义[J/OL]. 中华肺部疾病杂志(电子版), 2026, 19(01): 9-14.
[6] 马彬, 王启超, 王圣元, 赵虎林, 沈玥. 俯卧位通气管理在59例重症肺炎患者中的临床应用[J/OL]. 中华肺部疾病杂志(电子版), 2025, 18(06): 1012-1014.
[7] 倪琛, 邬步云, 毛慧娟. 2025年法国重症监护室中急性肾损伤的肾脏替代治疗指南解读[J/OL]. 中华肾病研究电子杂志, 2026, 15(01): 1-7.
[8] 娄熙冉, 袁雪燕, 邱海波, 刘玲. 急性呼吸窘迫综合征机械通气的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 262-266.
[9] 史楠, 袁雪燕, 刘玲, 邱海波. 急性呼吸窘迫综合征表型及药物治疗的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(03): 267-271.
[10] 曾思遥, 李悦, 孙振梓, 王洪亮. 重症肾脏:2025[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 129-133.
[11] 张莉, 谢剑锋, 张学超, 王静, 王伟, 钱淑媛. 重度急性呼吸窘迫综合征患者客观评估导向的精准化镇痛镇静一例[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 214-218.
[12] 伍宵, 唐颖, 张曦文, 邱海波. 表观遗传修饰调控急性呼吸窘迫综合征发病机制的研究进展[J/OL]. 中华重症医学电子杂志, 2026, 12(02): 202-207.
[13] 于丽娜, 张晓丽, 胡继宽, 张广稳, 钱会涛, 丁喜珍, 张颖, 陈齐红. 西维来司他钠调节Th17/Treg平衡改善多发伤相关ARDS患者氧合的随机对照研究[J/OL]. 中华临床医师杂志(电子版), 2025, 19(12): 919-925.
[14] 彭坤, 冯辉斌, 袁利学. 急性有机磷农药中毒并发急性呼吸窘迫综合征的危险因素相关性[J/OL]. 中华临床医师杂志(电子版), 2025, 19(09): 668-674.
[15] 张立, 李巧妮, 贺帅, 王朝霞, 宁小康. 连续性血液净化联合血液灌流在严重脓毒症合并急性呼吸窘迫综合征患者中的应用效果及PCT、hs-CRP、IL-6水平影响[J/OL]. 中华卫生应急电子杂志, 2026, 12(01): 26-31.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?